Gilead to appeal Indian Tamiflu decision
This article was originally published in Scrip
Gilead Sciences, whose patent application for the antiviral Tamiflu (oseltamivir) was rejected in India, is expected to appeal against the decision. Gilead said that it expects to vigorously defend its patent and the scientific innovation on which it's based, according to a report in the local media. Gilead's application has been opposed by Cipla and another domestic firm, Intermed (scripnews.com, April 23rd, 2009).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.